Ulixertinib hydrochloride salt form · hydrochloride · Parent Ulixertinib hydrochloride · Synonyms: BVD-523 hydrochloride

Ulixertinib hydrochloride is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases.

For research use only. Not for human or veterinary use.

Target ERK

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Ulixertinib hydrochloride structure

CAS No.: 1956366-10-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
500 mg	USD 685.00	BP-02521A-500mg	In stock	Get quote
1 g	USD 985.00	BP-02521A-1g	Inquire	Get quote
2 g	USD 1,650.00	BP-02521A-2g	In stock	Get quote
5 g	USD 2,850.00	BP-02521A-5g	In stock	Get quote
10 g	Inquire	BP-02521A-10g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

Biological activity

Identifiers

SMILES: O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO.[H]Cl
InChIKey: DKGYQCPFBWFTHM-FSRHSHDFSA-N

Specifications

MW (average): 469.7920
Formula: C₂₁H₂₃Cl₃N₄O₂
CAS No.: 1956366-10-1
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO,H2O

In vitro: DMSO : 100 mg/mL H2O : < 0.1 mg/mL

Documents

References

[1].Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.

[2].Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801.

Same target

Search ERK

Same research area

Search Cancer